Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: J Invest Dermatol. 2017 Oct 24;138(2):434–443. doi: 10.1016/j.jid.2017.09.030

Figure 7. Schematic representation of the biologic changes observed in chronic wounds treated with valsartan compared with those treated with placebo.

Figure 7.

α-SMA, alpha-smooth muscle actin; ARB, angiotensin II type 1 receptors blocker; iNOS, inducible nitric oxide synthase; MAPK, mitogen-activating protein kinase; SMAD, mothers against decapentaplegic; VEGF, vascular endothelial growth factor.